Supplementary Materials

This PDF file includes:

  • Fig. S1. Sos2 deletion does not alter cellular proliferation in MEFs expressing oncogenic RAS.
  • Fig. S2. Sos2 deletion does not alter GTP loading of mutant KRAS in MEFs.
  • Fig. S3. Introduction of SOS2 into Sos2−/− MEFs using different promoters to drive Sos2 expression.
  • Fig. S4. Inhibitor treatment of MEFs expressing mutant HRAS, NRAS, and KRAS blocks their corresponding downstream signaling pathways.
  • Fig. S5. There is a hierarchical requirement for SOS2 in promoting mutant RAS-driven cancer spheroid growth.
  • Fig. S6. Activated PI3K (p110α) cooperates with KRASG12V to transform Sos2−/− MEFs.
  • Fig. S7. Deletion of SOS2 using CRISPR/Cas9.
  • Fig. S8. Inhibitor treatment of YAPC cells blocks their corresponding downstream signaling pathways.
  • Table S1. sgRNA sequences used in this study.

[Download PDF]